This podcast aims to bring you a daily summary of the most relevant news in Pharma and BioTech. Check our website at: https://www.buzzsprout.com/2189790
…
continue reading
Pharma And BioTech News Podcasts
The Pharma Letter Podcast provides in-depth discussion and analysis focused on key trends, companies and events in the pharmaceutical and biotech industries. Our guests come from a broad array of sectors and business functions, from early stage research in biopharmaceuticals, to patient engagement and marketing, supply chain management and life sciences investing. Podcasts are typically 20-30 minutes in length and are released approximately once every two weeks.
…
continue reading
Welcome to Biotech Bulls & Breakthroughs! This brand new podcast from BioPharmCatalyst explores the dynamic world of biotech investing alongside long-time biotech trader Sheff from Sheff Station. Each month, we will be discussing current events in the biotech industry and how these events impact investors, as well as a discussion of upcoming catalysts in the biotech space.
…
continue reading
Welcome to The Pharma Podcast - Insights from industry experts and business leaders about important and current topics in Canadian Pharma, Biotech and Medtech.
…
continue reading
Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.
…
continue reading
The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing’s print and online coverage, which follows the industry’s biggest issues surrounding scale-up, technology innovations, regulations and more
…
continue reading
News and Analysis of the Biotech and Pharma Industry for Investors and Executives.
…
continue reading
A weekly audio digest of the most important news in drug development affecting the pharmaceutical and biotech industry
…
continue reading
BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries. Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences. Disclaimer https://biobizbuzz.com/disclaimer/
…
continue reading
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
…
continue reading
Welcome to the Ennovation Podcast, where we bring you the latest trends, insights and expertise in life sciences and regulatory affairs.
…
continue reading
This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.
…
continue reading
The impact of modern medicine on the human condition can’t be underestimated. From antibiotics to vaccines, medicine has changed the way our bodies work, answered deadly questions, and promised faster cures. But it’s not simple. Drug development is rife with tension. It costs a lot of money, and takes a long time. Most things fail. But when they succeed, they can make a tremendous difference in people’s lives. Where will the next breakthroughs come from? How will we pay for them? Who decides ...
…
continue reading
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of pe ...
…
continue reading
Join Hercules Capital in conversations with today’s top CEOs, CFOs, and investors in venture and private equity-backed companies. Learn about their strategies for financing rapid growth and scaling their businesses, as well as their unique interests and life stories that have shaped their paths to success.
…
continue reading
The Prospect Group is a leading global firm specializing in media, research, and consulting. We meet, and discuss the most relevant economic issues with, hundreds of the world’s leading business executives, political elites, and other influential personalities from a cross-section of industries and countries. Watch video interviews from and/or about Malaysia.
…
continue reading
This is Politics & Life Sciences (PLS) Radio which is an interplay of Life Sciences and Politics. I am your host Dean L. Fanelli, Ph.D. I am an Intellectual Property attorney in Washington, DC. My practice focuses on issues attendant to the Life Sciences industry. On PLS, we will explores cutting edge topics involving the Biotech and Pharma ecosystems and looks at political or governmental policy issues affecting the Biotech and Pharma industries. Each week, PLS will have amazing guests incl ...
…
continue reading
Are you working in healthcare market research or competitive intelligence or market intelligence? Do you often face information overload, from the pharma news portals, clinical trial registries, regulatory agencies, financial reports, investor releases, pharma summits, investment news, and financial summits etc.? It is hard to keep a track of all the forces (external and internal) that affects a product’s development and performance in the healthcare/ pharmaceutical market. We at RAS Life Sc ...
…
continue reading
1
Pharma and Biotech Daily: Top News in Gene Therapy, Vaccine Contracts, and Industry Updates
0:51
0:51
Play later
Play later
Lists
Like
Liked
0:51
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Intellia reported an adverse event in its gene therapy trial, causing its stock to drop, adding to existing safety concerns in gene therapy. Analysts downplayed the event, but patient deaths in other trials have raised…
…
continue reading
1
Pharma and Biotech Daily: Roche and Jazz's Promising Lung Cancer Combo, Trump's Tariffs Impact, and BioAgilytix's Drug Production Capabilities at BIO International
1:11
1:11
Play later
Play later
Lists
Like
Liked
1:11
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Roche and Jazz Pharmaceuticals presented data at ASCO showing that their drug combination improved survival in a phase III lung cancer trial, with analysts noting a strong treatment effect. Jazz has filed for FDA approva…
…
continue reading
1
Pharma and Biotech Daily: Key Updates in the World of Pharmaceuticals and Biotechnology
1:33
1:33
Play later
Play later
Lists
Like
Liked
1:33
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Regeneron's shares have dropped due to the failure of their dupixent follow-up drug, while Sanofi has acquired Blueprint for $9.5 billion to expand their rare disease portfolio. Bristol Myers Squibb is collaborating with …
…
continue reading
1
Forging the future of cell therapy: Bayer and BlueRock’s unique journey (Sponsored)
34:54
34:54
Play later
Play later
Lists
Like
Liked
34:54
In this episode of The Top Line, Fierce Biotech’s Chris Hayden sat down with Dr. Juergen Eckhardt of Bayer and Dr. Seth Ettenberg of BlueRock Therapeutics to discuss an innovative partnership that’s reshaping how big pharma teams up with biotech startups. BlueRock, a wholly owned subsidiary of Bayer, operates with the independence of a small biotec…
…
continue reading
1
Pharma and Biotech Daily: Catching up on the Latest in the Industry
0:47
0:47
Play later
Play later
Lists
Like
Liked
0:47
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The Summit's bispecific drug missed the survival endpoint in a global Phase III trial, but analysts remain optimistic about its potential to appeal to both Eastern and Western patient populations. Sanofi and Regeneron saw…
…
continue reading
1
Biopharma briefing: Q1 trends, gene therapy updates and ASCO preview
21:28
21:28
Play later
Play later
Lists
Like
Liked
21:28
Despite the long holiday weekend, news in biopharma never slows down. In this week’s episode of "The Top Line," the Fierce team breaks down some of the biggest stories from the past week. On the pharma side, Eric Sagonowsky and Kevin Dunleavy examine Big Pharma’s first-quarter 2025 performance. While most of the top 25 companies are still deliverin…
…
continue reading
1
355: Moderna’s vaccine hit, the MAHA report, and an ASCO preview
36:55
36:55
Play later
Play later
Lists
Like
Liked
36:55
The American Society of Clinical Oncology, or ASCO, kicks off its annual meeting this weekend in Chicago. We discuss what to watch at the meeting. Then, STAT’s infectious disease reporter Helen Branswell joins us to discuss RFK Jr.’s unprecedented move to strike Covid shot recommendations, and the cancellation of a $600 million contract with Modern…
…
continue reading
1
Pharma and Biotech Daily: Insider Trading, R&D Spending, and Acquisitions in the World of Pharmaceuticals
1:59
1:59
Play later
Play later
Lists
Like
Liked
1:59
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Former Chinook board member, Rouzbeh Haghighat, has been indicted for insider trading related to Novartis' $3.2 billion acquisition of the company. Despite this scandal, pharma R&D spending increased in 2024, climbing 1.5…
…
continue reading
1
Pharma and Biotech Daily: Navigating the Complexities of mRNA Technology and Gene Therapies
1:42
1:42
Play later
Play later
Lists
Like
Liked
1:42
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.A patient death has led to the halt of Rocket's gene therapy trial for Danon disease, due to complications from an acute systemic infection. This incident highlights the unpredictable nature of gene therapies and may pose…
…
continue reading
1
Pharma and Biotech Daily: Navigating Turbulent Times in the Biopharma Industry
0:50
0:50
Play later
Play later
Lists
Like
Liked
0:50
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The biopharma industry is currently facing challenges such as tariff threats and regulatory upheaval. The market has been described as 'moribund' with the need for companies to survive in these tough times. Recent top st…
…
continue reading
1
Pharma and Biotech Daily: Your Daily Dose of What Matters in the Industry
1:07
1:07
Play later
Play later
Lists
Like
Liked
1:07
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.A court has halted the Trump administration's plans to reduce and lay off employees in government agencies, citing a lack of authority. Meanwhile, a report called "Make American Healthy Again" criticizes pharmaceutical lobb…
…
continue reading
1
Why Boehringer and GSK are betting on Ochre
18:53
18:53
Play later
Play later
Lists
Like
Liked
18:53
This week on The Pharma Letter Podcast, we’re joined by Quin Wills, co-founder and chief scientific officer of UK biotech Ochre Bio. A physician-scientist with a background in genomics and computational biology, Quin has spent much of his career focused on the biology of liver disease — a path that has shaped Ochre’s approach to RNA-based therapies…
…
continue reading
1
Pharma and Biotech Daily: Stay Informed on the Latest Industry Updates
0:58
0:58
Play later
Play later
Lists
Like
Liked
0:58
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Sanofi has acquired Vigil for $470 million upfront, sparking interest in the Alzheimer's target Trem2 following previous failures. The FDA is encouraging states to import drugs from Canada to alleviate drug shortages. In o…
…
continue reading
1
354: Uncertainty in CRISPR world and the start of more M&A
41:30
41:30
Play later
Play later
Lists
Like
Liked
41:30
We chat about M&A deals picking up, leadership changes at Novo, and recent FDA advisory committee meetings for cancer drugs. We also bring on STAT reporter Jason Mast to talk about the latest research and sentiment at the annual American Society of Cell and Gene Therapy meeting.By STAT
…
continue reading
1
Ep. 2: FT US Pharma and Biotech Summit, Pharma Optimism in Uncertain Times | Biotech Bulls & Breakthroughs Podcast
24:47
24:47
Play later
Play later
Lists
Like
Liked
24:47
In this episode of Biotech Bulls and Breakthroughs, John Gagliano shares insights from the Financial Times US Pharma and Biotech Summit, discussing the optimism among pharma executives despite market volatility, the rise of innovation in China, trends in mergers and acquisitions, and the evolving role of AI in biotech. He also previews key highligh…
…
continue reading
1
Survival Strategies and Strategic Partnerships: The Latest in Pharma and Biotech
1:45
1:45
Play later
Play later
Lists
Like
Liked
1:45
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Moderna has withdrawn its application for a combination flu and COVID-19 vaccine after discussions with the FDA. The vaccine had shown efficacy in eliciting antibodies, but the company decided to pull the application. In …
…
continue reading
1
Radiopharmaceuticals and the Future of Nuclear Medicine with RadioMedix CEO Dr. Ebrahim Delpassand
37:35
37:35
Play later
Play later
Lists
Like
Liked
37:35
In this episode, Ayesha speaks with Ebrahim S. Delpassand, MD, Founder and CEO of RadioMedix, a company developing innovative radiopharmaceuticals for cancer diagnosis, monitoring and treatment. With a focus on both PET imaging and therapeutic radiopharmaceuticals labeled with alpha and beta emitters, RadioMedix is helping to shape the future of pr…
…
continue reading
1
Pharma and Biotech Daily: Pfizer's $6 Billion Bet, CRISPR Baby Success, and Bio-Rad's Antibody Discovery Platform
1:10
1:10
Play later
Play later
Lists
Like
Liked
1:10
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Pfizer has made a $6 billion bet on acquiring 3SBio's PD-1/VEGF antibody, despite being a late entrant to the space. This deal comes after Pfizer's partnership with Summit Therapeutics, causing some confusion about the p…
…
continue reading
1
Pharma and Biotech Daily: Navigating the Latest Industry News and Challenges
1:45
1:45
Play later
Play later
Lists
Like
Liked
1:45
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Regeneron has acquired ownership of 23andme for $256 million, promising to comply with consumer privacy policies. Makary's proposed rare disease pathway has sparked hope but raised questions among experts. At the American…
…
continue reading
1
Novo Nordisk CEO Lars Fruergaard Jorgensen to Depart Amid Share Decline: Pharma and Biotech Daily Update
0:32
0:32
Play later
Play later
Lists
Like
Liked
0:32
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Novo Nordisk CEO Lars Fruergaard Jorgensen is set to depart as the Danish pharma company's shares have been on a decline. During Jorgensen's eight-year tenure, the company saw significant growth in sales, profits, and shar…
…
continue reading
1
A Fierce breakdown of the 'most favored nation' executive order
15:20
15:20
Play later
Play later
Lists
Like
Liked
15:20
President Donald Trump put the pharmaceutical industry on notice early Monday with the signing of his "most favored nation" (MFN) executive order on drug prices. The order seeks to tie U.S. prices to significantly lower costs overseas. Many questions remain about how the measure will be implemented, and legal challenges are almost certain. To asses…
…
continue reading
1
Pharma and Biotech Daily: Senate Hearings, Accelerated Approvals, and Big Investments
1:13
1:13
Play later
Play later
Lists
Like
Liked
1:13
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.At a recent U.S. Senate hearing, Health and Human Services Secretary was questioned about cuts being made to the department and his stance on endorsing the measles vaccine during a growing outbreak. The hearing was tense at…
…
continue reading
1
353: Trump's drug-pricing plan and a potential Theranos 2.0
25:47
25:47
Play later
Play later
Lists
Like
Liked
25:47
We chat about the mixed sentiment in biotech markets these days and a new blood-testing company formed by Elizabeth Holmes' husband. We also bring on STAT's D.C. correspondent Daniel Payne to talk about President Trump's "most-favored nation" drug pricing policy and health secretary Robert F. Kennedy Jr.'s recent congressional hearing.…
…
continue reading
1
#37 - Redefining the CFO Role: From Operator to Strategic Advisor | M.G. Thibaut
30:30
30:30
Play later
Play later
Lists
Like
Liked
30:30
Share your thoughts with us! In the high-stakes world of startups, few roles have evolved more dramatically than that of the CFO. Today’s finance leader is expected to move beyond spreadsheets — shaping strategy, influencing product development, and building cross-functional trust. M.G. Thibaut has done all of that and more. In this episode, Eddie …
…
continue reading
1
Pharma and Biotech Daily: Breaking News and Innovations in Healthcare
2:31
2:31
Play later
Play later
Lists
Like
Liked
2:31
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ## Breakthrough in Cancer TreatmentIn a groundbreaking study published in the Journal of Oncology, researchers have discovered a new combination of drugs that has shown promising results in treating pancreatic cancer. Th…
…
continue reading
1
The Power of International Alliances: Unpacking the Swiss Biotech Report 2025
26:01
26:01
Play later
Play later
Lists
Like
Liked
26:01
In 2024, despite a challenging global financial climate, Switzerland’s biotech sector showed remarkable resilience, maintaining steady revenues of CHF 7.2 billion while achieving a 22% increase in capital investment. In this episode of BioBiz Buzz, host Mike Ward interviews Michael Altorfer, CEO of the Swiss Biotech Association, to discuss the find…
…
continue reading
1
Building the Future of Brain Health: Neuroscience Drug Development with Novartis’ Dr. Norman Putzki
27:30
27:30
Play later
Play later
Lists
Like
Liked
27:30
In this episode, Ayesha speaks with Norman Putzki, MD, Senior Vice President and Global Development Head of Neuroscience and Gene Therapy at Novartis, about the complexities and real-world challenges of bringing new therapies to patients with neurological diseases. Dr. Putzki discusses the challenges and opportunities in developing treatments for c…
…
continue reading
1
Pharma and Biotech Daily: Restructuring, Innovation Opportunities, and Industry Updates
1:10
1:10
Play later
Play later
Lists
Like
Liked
1:10
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Bayer has announced a restructuring that will result in 2,000 job cuts and a reduction in management layers. CEO Bill Anderson believes Trump's most favored nations policy could provide an opportunity for European countries…
…
continue reading
1
Pharma and Biotech Daily Podcast: Stay Informed on Drug Pricing, HIV Research, and Industry Updates
2:09
2:09
Play later
Play later
Lists
Like
Liked
2:09
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The White House has announced a new drug pricing policy that includes the revival of the most favored nations rule and extends to the private markets, leveraging the patent system, drug importation, and more. Meanwhile, L…
…
continue reading
1
[Solutions Spotlight] Hydrogenation: Bridging the gap between nitration and phosgenation
18:15
18:15
Play later
Play later
Lists
Like
Liked
18:15
Hydrogenation can serve as a critical link in chemical synthesis, particularly between nitration and phosgenation. When integrated strategically, it helps enable safer, more efficient production processes. To better understand this connection, we spoke with Dr. Luca Mantilli, R&D Chemist at Valsynthese, the fine chemicals division of Société Suisse…
…
continue reading
1
Pharma and Biotech Daily: AI Integration, Sanofi Cuts Ties, FDA Delays, and Trump's Drug Pricing Plan
0:45
0:45
Play later
Play later
Lists
Like
Liked
0:45
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The FDA is planning to fully integrate AI into their decision-making process by June 30, with individual centers starting the rollout immediately. Sanofi has cut off its antibody partner, leading to an 80% reduction in h…
…
continue reading
1
Angela Hwang on her pivot from Big Pharma to biotech
29:41
29:41
Play later
Play later
Lists
Like
Liked
29:41
Angela Hwang spent nearly three decades at Pfizer before joining Flagship Pioneering in 2025 as a CEO-partner and the CEO of Metaphore Biotechnologies. In this week’s episode of "The Top Line," the former Pfizer chief commercial officer speaks with Fierce Pharma Deputy Editor Angus Liu about her transition from marketing drugs at a Big Pharma compa…
…
continue reading
1
Pharma and Biotech Daily: Takeda's $30 Billion Investment and Industry Updates
0:47
0:47
Play later
Play later
Lists
Like
Liked
0:47
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Takeda's $30 billion investment in the U.S. is making headlines, along with their opposition to Trump's proposal on drug prices. The FDA's appointment of Vinay Prasad is stirring up mixed reactions within the industry. On …
…
continue reading
1
352: A firebrand takes oversight of vaccines, gene therapies
26:28
26:28
Play later
Play later
Lists
Like
Liked
26:28
Matt Herper joins Adam and Allison to examine Prasad's appointment and the band of outsiders now in charge of U.S. health agencies. He and Adam debate just how disruptive Prasad's tenure could be.By STAT
…
continue reading
1
ICON's AI strategy: faster, smarter trials
15:59
15:59
Play later
Play later
Lists
Like
Liked
15:59
This week on The Pharma Letter Podcast, we are joined by Tony Clarke, senior VP of IT digital operations at ICON (Nasdaq: ICLR). As a leader in digital transformation within clinical research, Tony has been at the forefront of implementing AI-driven solutions to enhance drug development. A global contract research organization (CRO), ICON has been …
…
continue reading
1
Pharma and Biotech Daily: The Latest in Industry News and Insights
1:57
1:57
Play later
Play later
Lists
Like
Liked
1:57
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo Nordisk predicts a brighter future for Wegovy with the end of the semaglutide shortage, but analysts remain skeptical as Eli Lilly's Zepbound gains ground in sales. The new HHS vaccine requirement has raised question…
…
continue reading
1
Rare Disease Innovation in an Evolving Industry with Amgen’s Dr. Sumita Bhatta
32:03
32:03
Play later
Play later
Lists
Like
Liked
32:03
In this episode, Ayesha speaks with Sumita Bhatta, MD, Vice President and Global Development Therapeutic Head of Rare Disease at Amgen. In the conversation, Dr. Bhatta shares insights on how large pharmaceutical companies like Amgen are approaching innovation and patient-centricity in the rare disease space. She also discusses the unique challenges…
…
continue reading
1
Breaking Down the Latest in Pharma and Biotech: Executive Orders, Investment Trends, and Industry News
0:58
0:58
Play later
Play later
Lists
Like
Liked
0:58
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.President Donald Trump has issued an executive order to expedite the timeline for building new facilities in the US while increasing inspections on foreign plants. Despite a drop in venture capital fundraising in the firs…
…
continue reading
1
Pharma and Biotech Daily: CRISPR Breakthroughs, FDA Concerns, and Vaccine Controversies
1:18
1:18
Play later
Play later
Lists
Like
Liked
1:18
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Two companies, Beam Therapeutics and Verve Therapeutics, have developed lead candidates using a safer alternative to conventional CRISPR called base editing. Clinical results have been promising. FDA insiders are calling …
…
continue reading
1
Pharma and Biotech News Roundup: Tax Policy vs Tariffs, FDA Rehiring Travel Staff, and Custom mRNA Sets
0:47
0:47
Play later
Play later
Lists
Like
Liked
0:47
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Amgen, along with other big pharma companies, is advocating for a "pro-growth tax policy" over tariffs to boost domestic pharmaceutical manufacturing. They are urging the Trump administration to consider tax policy as a be…
…
continue reading
1
ElevAAte and the push for East Asian American leaders in biopharma
35:59
35:59
Play later
Play later
Lists
Like
Liked
35:59
Although East Asians make up a significant share of entry-level roles in U.S. biopharma, few have risen to senior leadership positions. That disparity is what inspired the launch of ElevAAte—a new nonprofit founded this year to support and grow East Asian American leadership in the industry. In this week’s episode of "The Top Line," Fierce Pharma D…
…
continue reading
1
Rewriting the Future of Rare Cardiovascular Disease Through Epigenetic Innovation
23:29
23:29
Play later
Play later
Lists
Like
Liked
23:29
In this episode of BioBiz Buzz, your host Mike Ward sits down with Sten R. Sörensen, CEO of Cereno Scientific, to explore how the Swedish biotech is pioneering a new era in rare cardiovascular and pulmonary disease therapeutics. Cereno’s lead candidates, CS1 and CS014, leverage epigenetic modulation through histone deacetylase inhibition (HDACi) to…
…
continue reading
1
Breaking Barriers in Sexual Health: Dicot Pharma’s LIB-01 and the Future of ED Treatment
14:23
14:23
Play later
Play later
Lists
Like
Liked
14:23
This episode of BioBiz Buzz spotlights the rapidly growing global markets for erectile dysfunction (ED) and premature ejaculation (PE), conditions impacting over 500 million men worldwide. Your host Mike Ward interviews Elin Trampe, CEO of Dicot Pharma, who discusses the company’s innovative drug candidate, LIB-01. Unlike conventional therapies, LI…
…
continue reading
1
Pharma and Biotech Daily: Lilly's Revenue Soars, Moderna Cuts Costs, and HHS Implements New Vaccine Trial Policy
0:57
0:57
Play later
Play later
Lists
Like
Liked
0:57
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Lilly's revenue jumped by 45% in the latest quarter, driven by the success of their drugs Zepbound and Mounjaro. Moderna missed revenue expectations for the first quarter but plans to cut $1.5 billion in costs. Biogen ex…
…
continue reading
On this week’s episode of the Readout LOUD, we review President Trump’s first 100 days, the return of biotech M&A, strong drug launches, and Eli Lilly’s PBM problem. The first 100 days of the Trump administration have had a profound impact on federal health agencies, medical research, health policy and the biotech and pharmaceuticals industries. To…
…
continue reading
